- Christopher Moreau, CEO of Algernon Pharmaceuticals sat down with Brieanna McCutcheon to discuss Algernon’s unique approach to the psychedelics and health care sectors
- Algernon Pharmaceuticals is a clinical stage pharmaceutical development company that investigates safe, already approved drugs and compounds for new disease applications
- The company is advancing several compounds including Ifenprodil and DMT
- Algernon is closing enrollment for a 20-patient Ifenprodil study
- Shares of Algernon Pharmaceuticals Inc. (AGN) are currently trading at $7.99
Christopher Moreau, CEO of Algernon Pharmaceuticals sat down with Brieanna McCutcheon to discuss Algernon’s approach to the psychedelics and health care sectors.
Algernon Pharmaceuticals is a clinical-stage pharmaceutical development company. Algernon investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications.
Algernon is currently advancing a number of compounds including Ifenprodil for the treatment of chronic cough and N, N-Dimethyltryptamine, or DMT, a hallucinogenic drug for stroke treatment.
Algernon is currently closing enrollment for a 20-patient Ifenprodil study in Australia and New Zealand.
Shares of Algernon Pharmaceuticals Inc. (AGN) are currently trading at $7.99.
